ערך בספרים למניה: Invizyne Technologies (IZTC)

Invizyne Technologies Inc. is implementing cell-free synthesis methods, which radically reduces costs and provides significant pricing power. The reported book value per share demonstrates capitalization rates, where the -0.58 indicator determines the metric's magnitude. The software-biological approach lays the foundation for high FCF, although a lack of M&A funds shifts the focus toward scientific alliances with chemical behemoths.

An investor determines an asset's margin of safety through the ratio of net assets minus liabilities to the number of shares, which reveals the actual value of the ownership stake. For Invizyne Technologies Inc. (IZTC), which is developing a cell-free synthesis platform, the BVPS valuation demonstrates the capitalization level of tangible resources required to scale the technology, characterizing the company as a venture asset with a high technological component.